戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (right1)

通し番号をクリックするとPubMedの該当ページを表示します
1 re no postoperative complications or failure to observe the study protocol.
2  Forty-eight patients survived and/or completed the 6 month study protocol.
3 nse were analyzed by meta-regressions, as predefined in the study protocol.
4                       All analyses were prespecified in the study protocol.
5                    This study analysis was specified in the study protocol.
6                              All participants completed the study protocol.
7 up at 6 months (LTFU) was listed as the main outcome in the study protocol.
8 ients (69% men; median age, 77 [69-83] years) underwent the study protocol.
9 and established antimicrobial susceptibility using standard study protocols.
10 ts were followed for 3.1 +/- 1.5 years and 82 completed the study protocol 5-year visit.
11    Fourteen smoker and 13 non-smoker patients completed the study protocol and revealed similar clinical findings except
12 after FTC transmission, (2) follow-up contacts according to study protocol, and (3) medical intervention initiated after
13 ects receiving intravitreal anti-VEGF injections outside of study protocol as per standard of care were classified into R
14 ibility of incorporating short-interval exercises into WRIC study protocols by comparing the performance of WRICs and an
15 rted observer's effort, and the lack of a hypothesis-driven study protocol can lead to the occurrence of multiple sources
16                                                        This study protocol describes the design of a multicenter non-infe
17                                       Lack of experience in study protocol development and/or data analysis was associate
18 though the World Health Organization clinical drug efficacy studies protocol does not permit classification of patient ou
19 d trials and observational studies: 1) harmonization of the study protocols (eligibility criteria, treatment strategies,
20  DRSS score of at least 47 receiving ranibizumab 0.5 mg per study protocol experienced at least a 4-step DR severity impr
21             These extraction solvents can be used in future study protocols for the analysis of the fecal metabolome in g
22                                                     In this study, protocols for rapid detection of carbapenemase product
23                                                         The study protocol had been registered in PROSPERO (International
24                                                         The study protocol has been registered with PROSPERO (CRD42017079
25                                                         The study protocol has been registered with PROSPERO, number CRD4
26                                                         The study protocol has been registered with PROSPERO, number CRD4
27                                                         The study protocol has been registered with PROSPERO, number CRD4
28                                                         The study protocol has been registered with PROSPERO, number CRD4
29 /- 2.2 years, BMI 25.1 +/- 1.0 kg/m(2)) participated in two study protocols in random order over two consecutive days.
30                               If corroborated by additional studies, protocols incorporating VCE could expand the scope o
31                                                         The study protocol is registered with PROSPERO (CRD42018087022).
32                                                         The study protocol is registered with PROSPERO, number CRD4201401
33                                                         The study protocol is registered with PROSPERO, protocol CRD42016
34 lts A total of 102 women were enrolled and 99 completed the study protocol (mean age, 51 years +/- 11 [standard deviation
35          All participants were followed through the initial study protocol of 24 months and were approached to enter an e
36                Of the 59 patients who underwent surgery per study protocol, persistent DCIS remained in 50 patients (85%)
37 rticipants or site anomalies, such as failures to adhere to study protocols that could negatively affect study validity.
38 he TODAY Study investigators proposed a modification of the study protocol to collect biological specimens from participa
39 s in TOPCAT between Russia/Georgia study sites suspected of study protocol violations and sites in the Americas ( P=0.12
40                                        On May 30, 2012, the study protocol was amended to allow crossover from control to
41                                       On Sept 12, 2012, the study protocol was amended to allow patients with disease pro
42 en informed consent was obtained from all patients, and the study protocol was approved by the committee on human researc
43                                          Trial registry The study protocol was approved by the Ethics Committee of Qom Un
44                                   Materials and Methods The study protocol was approved by the institutional review board
45                                                         The study protocol was registered at Prospero (number 162811).
46                                                         The study protocol was registered at the German Clinical Trials R
47                                          Using a laboratory study protocol, we show that SD individuals can maintain info
48 73 tests, mostly biopsies (n = 44, 60%) as requested by the study protocol, were triggered.
49 althy subjects participated in an A-B-A (withdrawal design) study protocol, which involved leaning at 45o for up to 90 s
50 irty-seven eyes of 37 patients were enrolled in the initial study protocol, with 19 eyes randomized to fresh and 18 to fr